Be useful as an agent for the prophylaxis or treatment of diseases that express human SGLT inhibitory activity, caused by diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc., to hyperglycemia, the present invention is represented by the following acceptable salt thereof or a pharmacologically fused heterocyclic derivative represented by the general formula (I), or a prodrug thereof wherein, H, OH, R 1 ~R 4 amino group or the like and R 5 Q is an alkylene, alkenylene, etc. following ring (R1), a group represented by (R2) below the ring aryl or heteroaryl group ring A H, OH, halogen atom, optionally substituted alkyl groups R 6 is G is a group represented by (G-2) following general formulas (G-1) (OH H, F or E 1 H, F, methyl, etc. E 2)], and containing the same The object of the present invention is to provide a pharmaceutical use thereof and pharmaceutical compositions.本発明は、ヒトSGLT活性阻害作用を発現し、糖尿病、食後高血糖、耐糖能異常、糖尿病性合併症、肥満症等の、高血糖症に起因する疾患の予防又は治療剤として有用な、下記一般式(I)で表される縮合複素環誘導体またはその薬理学的に許容される塩、或いはそれらのプロドラッグ〔式中、R1~R4はH、OH、アミノ基等;R5及びR6はH、OH、ハロゲン原子、置換可アルキル基等;Qはアルキレン、アルケニレン等;環Aはアリール基又はヘテロアリール基;下記環(R1)は、下記環(R2)で表される基;Gは下記一般式(G-1)又は(G-2)で表される基(E1はH、F又はOH;E2はH、F、メチル基等)〕、並びにそれを含有する医薬組成物及びその医薬用途を提供するものである。
